Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AZ’s Asthma Drug Tezepelumab Clears MHLW Panel Review; BMS’ Psoriasis Med, MSD/Sanofi Jabs Too
August 30, 2022
- AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
- MHLW’s Health Service Bureau to Seek Funding for “Income Security System” for Antimicrobials for FY2023
August 29, 2022
- MHLW’s Health Policy Bureau to Seek Budget for Research into Integrating Drug Supply Info, Clarification of Generic Ratio
August 29, 2022
- MHLW Begins Discussions on Potential Use of Non-Doctor/Nurse Healthcare Professionals as Vaccinators
August 29, 2022
- MHLW’s Pharma Bureau to Request Budget to Promote RWD Use in Regulatory Filing for FY2023
August 26, 2022
- MHLW to Seek 400 Million Yen for AI-Powered Drug Discovery for Cancer: FY2023 Budget Request
August 26, 2022
- MHLW Seeks 2-Year Extension of Raise on R&D Tax Credit Ceiling: FY2023 Reform Request
August 26, 2022
- MHLW’s Health Policy Bureau Eyes COI Management System, Upgraded Clinical Research Database: FY2023 Budget Request
August 26, 2022
- MHLW to Request a 33.26 Trillion Yen General Account Budget for FY2023
August 26, 2022
- Lilly’s Tirzepatide in Line for Approval as Early as September as Japan’s 1st GIP/GLP-1 Agent
August 26, 2022
- Japan Approves Label Expansions for Lynparza, Ultomiris, Keytruda, Tagrisso, and More
August 25, 2022
- 1st Meeting of New Drug Distribution and Pricing Panel Set for Aug. 31
August 25, 2022
- AstraZeneca’s COVID Cocktail Up for Aug. 29 PAFSC Session; Comirnaty Pediatric Booster Too
August 23, 2022
- MHLW to Seek Budget for Integrated Drug Supply Info System for FY2023
August 23, 2022
- MHLW to Boost Orphan Program to Fuel New Drug Development: FY2023 Budget Request
August 23, 2022
- After Repeated Scandals, PMDA Sets Up New Division to Provide GMP Inspection Know-How to Prefectures
August 22, 2022
- Study Group Agrees on Need to Craft Transparent Rules for Use of Pseudonymized Info
August 22, 2022
- Operational Issues of Emergency Approval Scheme Will Be Addressed If Needed: Pharma Bureau Chief
August 19, 2022
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…